List of Excipients in Branded Drug BINOSTO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	BINOSTO	alendronate sodium	0178-0101	ACESULFAME POTASSIUM
Mission Pharmacal Company	BINOSTO	alendronate sodium	0178-0101	ANHYDROUS CITRIC ACID
Mission Pharmacal Company	BINOSTO	alendronate sodium	0178-0101	MONOSODIUM CITRATE

BINOSTO Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BINOSTO is a 70 mg once-weekly effervescent alendronate sodium formulation for postmenopausal osteoporosis. Its commercial differentiation depends on rapid dispersion in water, palatability, reliable buffering, low moisture exposure, and administration compliance rather than on a new active ingredient. The strongest excipient opportunities are in effervescent-system optimization, flavor and taste management, moisture-control packaging, low-sodium reformulation, and platform licensing for other poorly tolerated oral drugs.[1]

What is BINOSTO and how does its formulation work?

BINOSTO contains alendronate sodium equivalent to 70 mg of alendronic acid. The tablet is dissolved in approximately 4 ounces of plain water before administration. The patient drinks the solution after the effervescence has stopped and before the solution stands for more than five minutes.[1]

The dosage form uses an acid-base effervescent system. Water activates the reaction between acidic and alkaline components, generating carbon dioxide and dispersing the active ingredient. The resulting solution is intended to reduce the need to swallow a conventional large tablet.

Product attribute	BINOSTO profile
Active ingredient	Alendronate sodium
Strength	70 mg
Dosing frequency	Once weekly
Dosage form	Effervescent tablet for oral solution
Therapeutic category	Bisphosphonate for osteoporosis
FDA pathway	New drug application
Administration	Dissolve in plain water before drinking
Primary formulation value	Dispersion and swallowability
Principal formulation risks	Moisture sensitivity, taste, sodium load, reaction control
Key commercial comparator	Generic alendronate tablets and oral solutions

The FDA label identifies the inactive-ingredient system as including citric acid anhydrous, sodium bicarbonate, sodium carbonate anhydrous, sodium saccharin, and lemon flavor.[1] The excipients perform distinct technical functions:

• Citric acid provides the acidic component of the effervescent reaction and contributes to taste.
• Sodium bicarbonate and sodium carbonate provide alkalinity and carbon dioxide generation.
• Sodium saccharin provides high-intensity sweetness.
• Lemon flavor supports palatability and helps manage the inherent taste of the buffer system.
• The tablet matrix must maintain mechanical integrity while remaining sufficiently soluble and reactive in water.

What excipients protect BINOSTO’s commercial performance?

The most important excipient decisions concern the balance between reaction speed, tablet stability, solution pH, flavor, and patient tolerability.

Effervescent acid-base system

The citric acid and carbonate combination is the core delivery technology. Its ratio affects:

1. Effervescence rate.
2. Final solution pH.
3. Residual alkalinity or acidity.
4. Carbon dioxide release.
5. Alendronate dissolution and dispersion.
6. Taste after reconstitution.
7. Tablet stability under humidity.

A formulation with excessive carbonate can create a strongly alkaline taste and increase sodium exposure. Excess acid can produce a sour taste, change the final pH, and affect stability. The formulation must also avoid premature reaction during manufacturing and storage.

This creates a commercial opening for excipient suppliers that can provide controlled-particle-size citric acid, low-moisture sodium bicarbonate, dense sodium carbonate, and co-processed effervescent systems. Particle morphology, water activity, and bulk density can affect both compression and dissolution performance.

Sweetener and flavor system

BINOSTO uses sodium saccharin and lemon flavor. This is a relatively simple palatability system, but it leaves room for differentiated development.

Potential alternatives include:

• Sucralose or acesulfame potassium for reduced aftertaste.
• Steviol glycosides for clean-label positioning, subject to taste and regulatory review.
• Natural lemon, citrus, or lime flavors.
• Encapsulated flavors to improve storage stability.
• Taste-masking combinations that reduce the perception of alkaline salts.
• Flavor systems designed for older adults with reduced taste sensitivity.

Flavor changes may appear commercially minor, but they can affect adherence in a chronic, once-weekly product. A better-tasting formulation could support a reformulation strategy, a line extension, or a private-label partnership if supported by appropriate regulatory protection.

Compression and dissolution excipients

Effervescent tablets require a narrow balance between hardness and rapid dissolution. Conventional tablet excipients can absorb moisture or interfere with effervescence. Candidate technologies include:

• Direct-compression mannitol with low hygroscopicity.
• Anhydrous fillers with controlled water activity.
• Co-processed excipients that improve flow and compression.
• Dry binders compatible with acidic and alkaline salts.
• Lubricants selected to avoid delayed wetting.
• Granulation approaches that isolate reactive components until use.

The commercial value lies in improving tablet robustness without slowing dispersion. A harder tablet that remains stable during shipping may still fail if it leaves excessive residue or dissolves too slowly in the patient’s glass.

What formulations are protected by BINOSTO-related intellectual property?

BINOSTO’s formulation differentiation is more likely to depend on effervescent-composition claims, dosage-form claims, manufacturing processes, and product-specific regulatory exclusivity than on the basic use of alendronate.

Relevant claim categories may include:

• An effervescent tablet containing alendronate and a defined acid-base system.
• Ratios of citric acid, bicarbonate, and carbonate.
• Defined dissolution or dispersion behavior.
• Tablet hardness and friability parameters.
• Moisture-control manufacturing conditions.
• Packaging that preserves stability.
• Methods of administering alendronate as a pre-dissolved oral solution.
• Methods of reducing gastrointestinal exposure or improving patient administration.

A generic company may avoid a narrow formulation patent by changing the flavor, sweetener, acid, base, tablet size, or packaging. A broader patent covering the combination of active ingredient, effervescent couple, and performance limitations would create a stronger barrier.

Patent status must be assessed against the current FDA Orange Book and relevant national registers. The Orange Book identifies patents and regulatory exclusivity associated with approved products, but it does not capture every manufacturing, formulation, trade-secret, or foreign patent right.[2]

When does BINOSTO lose exclusivity?

BINOSTO is an established product with no biologic biosimilar pathway. Its principal competitive risk is generic or follow-on alendronate, not biosimilar substitution.

The relevant exclusivity questions are:

Exclusivity category	BINOSTO relevance
New chemical entity exclusivity	Not applicable in the conventional sense because alendronate was previously approved
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Must be checked in FDA records
Formulation patent protection	Potentially relevant
Method-of-use patent protection	Potentially relevant
Orange Book-listed patents	Must be reviewed for current status
ANDA competition	Possible if a generic can satisfy product-specific requirements
505(b)(2) competition	Possible for a materially different oral solution or effervescent product

The commercial loss of exclusivity does not necessarily occur on a single date. It may develop in stages:

1. Patent expiry or invalidation.
2. First ANDA approval.
3. Launch following certification, litigation, or settlement.
4. Price erosion after multiple entrants.
5. Substitution pressure from conventional alendronate tablets.

The FDA Orange Book is the controlling public source for listed patents and expiration information. Product labels and approval histories should be reviewed with the Orange Book because patent listings can change over time.[1,2]

Which companies could challenge BINOSTO with generic or follow-on products?

Potential competitors fall into four groups:

Conventional alendronate manufacturers

Companies already selling generic alendronate tablets have manufacturing expertise, established distribution, and payer access. Their products are usually cheaper but do not replicate BINOSTO’s effervescent administration.

Effervescent-tablet specialists

Manufacturers with experience in soluble tablets, electrolyte products, analgesics, or gastrointestinal medicines may be better positioned to reproduce the dosage form. The technical barrier is higher than for a conventional immediate-release tablet because the product must control moisture and effervescence.

505(b)(2) developers

A 505(b)(2) applicant could develop an alternative alendronate oral solution, effervescent product, flavored liquid, or modified administration method. This route may be attractive if the applicant can establish reliance on existing alendronate safety data while pursuing differentiated labeling or formulation claims.[3]

Contract development and manufacturing organizations

CDMOs with effervescent-tablet platforms can offer development packages covering formulation, tube or blister packaging, stability testing, and commercial-scale manufacture. These companies are potential licensing partners for a reformulated BINOSTO product or a competing alendronate presentation.

No biosimilar risk exists because alendronate is a small-molecule drug. A “biosimilar BINOSTO” would not be the relevant regulatory or commercial category.

What Paragraph IV risks exist for BINOSTO?

A Paragraph IV certification could challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The commercial attractiveness of such a challenge depends on:

• The number and breadth of listed patents.
• Whether the patents cover the effervescent product itself or only narrow formulation parameters.
• Whether a generic can design around the claims.
• The remaining market value of BINOSTO.
• The expected cost of formulation and stability development.
• The probability of a 30-month stay following patent litigation.
• The availability of a non-infringing conventional or liquid alendronate product.

A generic applicant would probably face a greater formulation burden than an applicant copying a standard alendronate tablet. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements, while controlling the product’s effervescence, solution behavior, and labeling instructions.[3]

Patent litigation and settlement terms should be checked through PACER, FDA records, and company disclosures. Public records should distinguish between a filed Paragraph IV notice, a district-court complaint, a settlement agreement, and an actual commercial launch. Those events have different commercial effects.

How strong is the BINOSTO patent estate?

BINOSTO’s patent estate is strongest where claims combine several technical limitations that are difficult to remove without damaging the product’s performance.

Potentially stronger claim features

• A defined acid-to-base ratio.
• Specific dissolution or dispersion thresholds.
• A narrow pH range after reconstitution.
• Moisture limits linked to tablet stability.
• A defined tablet composition with alendronate and effervescent salts.
• Packaging and manufacturing controls tied to shelf life.
• Administration instructions supported by clinical or pharmacokinetic data.

Weaker claim features

• Lemon flavor alone.
• Sodium saccharin alone.
• Generic use of citric acid and sodium bicarbonate.
• Conventional tablet compression methods.
• Broad claims covering alendronate administration without technical limitations.

Trade secrets may supplement patents. Critical know-how may include blending order, humidity controls, compression force, flavor incorporation, packaging line conditions, and stability specifications. These rights can delay a competitor but are difficult to enforce against independent development.

What excipient opportunities exist for BINOSTO reformulation?

The most commercially credible opportunities are below.

Opportunity	Technical objective	Commercial value
Reduced-sodium system	Lower sodium contribution from carbonate salts	Differentiated labeling and broader patient positioning
Improved taste	Reduce alkaline and sulfurous aftertaste	Better adherence and patient acceptance
Faster dissolution	Shorten preparation time	Lower administration friction
Moisture-resistant tablet	Improve shelf life and transport robustness	Lower manufacturing loss and broader geographic distribution
Unit-dose packaging	Protect each tablet from humidity	Better stability and dispensing convenience
Alternative sweetener	Replace or supplement saccharin	Product differentiation
Low-residue formula	Reduce sediment or undissolved material	Better patient experience
Child-resistant, senior-friendly packaging	Improve handling without increasing opening difficulty	Retail and adherence advantage
Lower tablet mass	Reduce packaging and shipping burden	Manufacturing and logistics savings

A reduced-sodium version is technically attractive but requires careful evaluation. Effervescent systems commonly rely on sodium salts, and simply removing sodium may impair reaction capacity, pH control, tablet strength, or dissolution. Potassium or calcium-based alternatives could create new safety and labeling issues and would not be direct substitutes.

Moisture protection is a more practical near-term opportunity. Tube packaging with desiccant, high-barrier blister systems, foil overwraps, and improved closure technology can protect effervescent tablets without changing the active formulation. Packaging claims may support a line extension even where the composition remains substantially unchanged.

How does BINOSTO compare with conventional generic alendronate?

Attribute	BINOSTO	Generic alendronate tablet
Administration	Dissolved in water	Swallowed whole
Patient experience	May help patients who struggle with tablets	Familiar but can be difficult to swallow
Cost position	Generally higher formulation and packaging cost	Low-cost commodity product
Excipient complexity	High	Moderate
Moisture sensitivity	High	Lower relative complexity
Differentiation	Effervescence, flavor, dispersion	Price and availability
Substitution	May not be directly substitutable with a conventional tablet	Broad pharmacy availability
Competitive moat	Formulation, brand, and patient preference	Scale and price

BINOSTO’s commercial opportunity is strongest in patients who have difficulty swallowing conventional tablets, prefer a dissolved formulation, or need an administration format that supports weekly dosing. Its weakness is cost competition from generic alendronate tablets.

What FDA regulatory strategy applies to new BINOSTO-like products?

A product with the same active ingredient and materially different formulation may be pursued through an ANDA or 505(b)(2) application, depending on the proposed dosage form, reference-product relationship, formulation differences, and FDA requirements.[3]

An ANDA-oriented strategy would emphasize pharmaceutical equivalence, bioequivalence, manufacturing controls, and avoidance of listed patent claims. A 505(b)(2) strategy may be more suitable for:

• A new effervescent formulation.
• A ready-to-drink alendronate solution.
• A novel flavor or low-sodium system.
• A product with modified administration instructions.
• A reformulation supported by clinical adherence data.

Excipient changes can trigger additional studies if they affect absorption, dissolution, stability, dose delivery, or labeling. FDA guidance and product-specific recommendations should determine the evidence package.[3,4]

What licensing deals and commercial partnerships are most attractive?

The most viable licensing structures involve:

1. Effervescent formulation technology licensed to an established osteoporosis company.
2. Excipient and packaging partnerships with a generic manufacturer.
3. Regional rights for a lower-cost alendronate effervescent product.
4. Co-development of a new flavored or reduced-sodium presentation.
5. Platform licensing for other oral drugs with swallowability or dissolution problems.
6. CDMO agreements combining formulation ownership with commercial supply.

A platform deal may be more valuable than a single-product agreement if the technology can support calcium, iron, analgesic, gastrointestinal, or pediatric products. The main diligence points are freedom to operate, moisture stability, scale-up yield, tablet performance, and regulatory precedent.

What revenue exposure exists if generic competition reaches BINOSTO?

Revenue erosion would likely depend on whether the entrant copies the effervescent dosage form or competes only with conventional alendronate.

• A conventional generic tablet would pressure price and payer coverage but may not fully replace BINOSTO for patients who prefer dissolved dosing.
• A lower-priced effervescent generic would create direct substitution risk.
• Multiple effervescent entrants could reduce prices rapidly because the active ingredient is mature and inexpensive.
• A differentiated flavor, packaging format, or low-sodium product could preserve a premium segment.
• A strong patient-support and adherence program could support retention but would not prevent formulary substitution.

The principal asset is therefore the dosage-form preference, not alendronate exclusivity alone.

Key Takeaways

• BINOSTO’s value is concentrated in its effervescent delivery system and administration convenience.
• Citric acid, sodium bicarbonate, sodium carbonate, sodium saccharin, and lemon flavor are central to the product’s technical and commercial profile.[1]
• The highest-value excipient opportunities are moisture control, taste improvement, low-residue dissolution, and potentially lower-sodium systems.
• Generic tablet competition is a larger price threat than biosimilar competition, which is not applicable to alendronate.
• Direct effervescent competitors would face higher formulation, packaging, and stability requirements than conventional tablet manufacturers.
• Orange Book review, patent-family analysis, and Paragraph IV monitoring are necessary to assess launch timing and freedom to operate.[2]
• A 505(b)(2) pathway may be attractive for materially different oral solutions, flavors, or effervescent presentations.[3]
• Excipient and packaging platforms could have licensing value beyond BINOSTO if they can be applied to other oral drugs.

FAQs

Can a generic manufacturer replace BINOSTO with a standard alendronate tablet?

A standard alendronate tablet can compete therapeutically, but it may not be directly substitutable at the pharmacy level for BINOSTO because the dosage forms and administration instructions differ.

Does BINOSTO require a special excipient manufacturing process?

The product requires controlled handling of moisture-sensitive acid and carbonate components. Blending, compression, environmental humidity, and packaging controls are more important than for a conventional immediate-release tablet.

Could BINOSTO be reformulated without sodium?

A sodium-free effervescent system is technically possible in principle, but it would require new development work because sodium salts contribute to carbon dioxide generation, alkalinity, tablet mass, dissolution, and taste.

Is the lemon flavor itself patentable?

A lemon flavor alone is unlikely to provide a strong patent position. Protection would be stronger if the flavor were part of a defined composition linked to stability, palatability, dissolution, or a clinically relevant administration benefit.

What is the best commercial entry strategy for a BINOSTO competitor?

A direct effervescent generic can target price-sensitive patients, while a 505(b)(2) product can pursue differentiation through flavor, packaging, sodium reduction, ready-to-drink delivery, or adherence-focused labeling.

References

1. U.S. Food and Drug Administration. (n.d.). BINOSTO (alendronate sodium) effervescent tablet prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations and abbreviated new drug application requirements.
4. U.S. Food and Drug Administration. (2016). ANDAs for certain highly soluble drugs: Biopharmaceutics classification system-based waivers. Guidance for industry.